Table 2. Association between polygenic risk score (PRS quantitative) and grade 3 bevacizumab-induced hypertension in each study for the most statistically significant meta-analysis p-value using SNPs associated with systolic blood pressure (SBP) and diastolic BP (DBP).
OR per SD: odds ratio per standard deviation; CI: confidence interval; AUC: area under the curve.
| p-value | OR per SD (95% CI) | PRS R2 (adjusted) | AUC (95% CI) | Number of SNPs | |
|---|---|---|---|---|---|
| SBP (p-value threshold <10×10−29) | |||||
| Meta-analysis | 0.0077 | 1.31 (1.07–1.60) | |||
| CALGB 80303 | 0.3359 | 0.85 (0.52–1.39) | 0.012 | 0.62 (0.48–0.76) | 67 |
| CALGB 40503 | 0.1511 | 1.40 (0.89–2.22) | 0.028 | 0.64 (0.52–0.75) | 66 |
| CALGB 90401 | 0.0012 | 1.97 (1.19–3.26) | 0.086 | 0.73 (0.62–0.83) | 66 |
| CALGB 40502 | 0.0956 | 1.22 (0.90–1.65) | 0.012 | 0.56 (0.50–0.66) | 65 |
| DBP (p-value threshold <10×10−39) | |||||
| Meta-analysis | 0.0209 | 1.27 (1.04–1.56) | |||
| CALGB 80303 | 0.5245 | 0.79 (0.49–1.27) | 0.005 | 0.60 (0.46–0.73) | 53 |
| CALGB 40503 | 0.1572 | 1.39 (0.89–2.18) | 0.029 | 0.57 (0.44–0.71) | 53 |
| CALGB 90401 | 0.0087 | 2.15 (1.33–3.47) | 0.061 | 0.69 (0.59–0.80) | 53 |
| CALGB 40502 | 0.2093 | 1.29 (0.96–1.74) | 0.007 | 0.56 (0.48–0.64) | 49 |